2m 2m 2m 2m 2m 2m 2m
Ascentage Sp ADS (AAPG)
NASDAQ
$17.05-$0.08 (-0.47%)
Price as of Jun 23, 2026 2:53 PM EDT- $1.6BMarket Cap
- -53.89%1-Year Change
- BiotechnologyIndustry
Ascentage Sp ADS (AAPG)
$17.05-$0.08 (-0.47%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 499.3M -26.41% | 678.4M N/A | |
Cost of Revenue | 46.7M +72.62% | 27.0M N/A | |
Gross Profit | 525.2M -44.81% | 951.6M N/A | |
Sales and Marketing Expense | 353.6M +80.43% | 196.0M N/A | |
Research and Development Expense | -1.1B +20.08% | -947.2M N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | N/A N/A | N/A N/A | |
Operating Profit | N/A N/A | N/A N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | -49.5M -16.43% | -59.3M N/A | |
Interest Income and Expense and Net | -49.5M -16.43% | -59.3M N/A | |
Total Nonoperating Income and Expense | 103.5M +80.43% | 57.4M N/A | |
Income before Taxes | -1.2B +206.40% | -405.7M N/A | |
Income Taxes | 6.9M -33.43% | 10.4M N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -1.2B +206.40% | -405.7M N/A | |
Net Income from Continuing Operations Applicable to Common | -1.2B +206.40% | -405.7M N/A | |
Basic EPS and Net Income | -3.49 +160.45% | -1.34 N/A | |
Diluted EPS and Net Income | -3.49 +160.45% | -1.34 N/A | |
Basic Weighted Average Shares | 356.1M +17.90% | 302.1M N/A | |
Diluted Weighted Average Shares | 356.1M +17.90% | 302.1M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 1.2B +33.89% | 893.1M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 1.2B +33.89% | 893.1M N/A | |
Total Current Assets | 2.9B +99.72% | 1.5B N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 781.2M -8.03% | 849.5M N/A | |
Total Long-Term Assets | 1.0B -10.86% | 1.1B N/A | |
Total Assets | N/A N/A | N/A N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 1.0B +258.62% | 290.0M N/A | |
Total Current Liabilities | 1.6B +40.87% | 1.2B N/A | |
Total Long-Term Debt | 1.3B +54.35% | 813.6M N/A | |
Total Long-Term Liabilities | 986.0M -16.23% | 1.2B N/A | |
Total Liabilities | 2.6B +12.19% | 2.3B N/A | |
Retained Earnings | -844.0M -8.13% | -918.7M N/A | |
Total Stockholders Equity | 1.3B +386.65% | 274.2M N/A | |
Total Shares Outstanding | 373.3M +18.43% | 315.2M N/A | |
Cash Flow | |||
Cash from Operating Activities | -1.2B +954.38% | -111.4M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -1.0B +176.23% | -362.0M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 2.5B +706.98% | 314.8M N/A | |
Financials Ratio | |||
Gross Margin | 90.65% N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | N/A N/A | N/A N/A | |
Return on Equity | -154.56% N/A | N/A N/A | |
Revenue Growth | -26.41% N/A | N/A N/A | |
Current Ratio | 1.79 N/A | N/A N/A | |
Cash Ratio | 0.73 N/A | N/A N/A | |
Debt-to-Equity Ratio | 1.72 N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow